Q1 2025 EPS Estimates for Merus (NASDAQ:MRUS) Lowered by Analyst

Merus (NASDAQ:MRUSFree Report) – Stock analysts at William Blair dropped their Q1 2025 EPS estimates for shares of Merus in a note issued to investors on Tuesday, May 28th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.84). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.14) per share. William Blair also issued estimates for Merus’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($3.14) EPS.

Several other equities research analysts also recently issued reports on the stock. Stifel Nicolaus lifted their price target on shares of Merus from $65.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of Merus in a research note on Friday, May 24th. BMO Capital Markets increased their price target on Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Bank of America lifted their price objective on Merus from $52.00 to $61.00 and gave the stock a “buy” rating in a report on Friday, May 24th. Finally, Truist Financial began coverage on Merus in a research note on Thursday, March 28th. They set a “buy” rating and a $69.00 target price for the company. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.80.

Check Out Our Latest Analysis on Merus

Merus Stock Up 6.1 %

MRUS opened at $57.30 on Thursday. The firm’s 50 day moving average is $45.30 and its 200-day moving average is $38.08. Merus has a 52-week low of $19.81 and a 52-week high of $61.61. The firm has a market capitalization of $3.36 billion, a P/E ratio of -20.60 and a beta of 1.10.

Merus (NASDAQ:MRUSGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The company had revenue of $7.89 million for the quarter, compared to analysts’ expectations of $8.94 million. Merus had a negative return on equity of 44.13% and a negative net margin of 390.36%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Quadrant Capital Group LLC lifted its holdings in shares of Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 343 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Merus by 64.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 828 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Merus during the first quarter valued at $72,000. SG Americas Securities LLC bought a new position in shares of Merus during the first quarter worth about $108,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Merus by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,459 shares during the period. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Featured Stories

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.